Spacelabs Healthcare has closed its acquisition of Del Mar Reynolds Medical, the cardiac division of UK group Ferraris. Hawthorne, California-based Spacelabs had agreed in July to acquire the business for £14m ($25.5m) in cash (see Clinica No 1213, p 15). The acquisition will provide Spacelabs' with a broader presence in the UK and German cardiac monitoring markets, as well as double the size of its existing core lab business.
Spacelabs completes Del Mar Reynolds Medical acquisition:
Spacelabs Healthcare has closed its acquisition of Del Mar Reynolds Medical, the cardiac division of UK group Ferraris. Hawthorne, California-based Spacelabs had agreed in July to acquire the business for £14m ($25.5m) in cash (see Clinica No 1213, p 15). The acquisition will provide Spacelabs' with a broader presence in the UK and German cardiac monitoring markets, as well as double the size of its existing core lab business.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
• By
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
• By
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
• By
Existing legislation already offers a route, albeit rarely used, for orphan and innovative devices to reach the market more quickly. It should be used more; manufacturers and notified bodies do not need to wait for official changes to the EU’s medtech regulations.
• By
President Trump’s CDC director nominee was pulled after vaccine positions appeared too extreme for some Republicans, but the nominations to lead the FDA and NIH advanced to the Senate floor despite last-minute drama.
• By
Insight into the knock-on effects on innovation adoption and procurement is keenly awaited by medtechs.